![]() ![]() ![]() The Company will also retain worldwide rights to any products for which Roche elects not to exercise its applicable option. For up to two of the five collaboration programs, if Roche exercises its option, the Company will retain commercialization rights in the United States for the Licensed Products, and Roche will receive commercialization rights outside of the United States for the Licensed Products. For up to three of the five collaboration programs, if Roche exercises its option, Roche will receive worldwide, exclusive commercialization rights for Licensed Products. Such option rights are triggered upon the achievement of Phase I proof-of-concept. Under the Agreement, Roche is granted up to five option rights to obtain an exclusive license to exploit products derived from the collaboration programs (the “Licensed Products”) in the field of cancer immunotherapy. T he parties have agreed to the targets for three of the collaboration programs, all of which are expected to begin in 2016, and t he parties have agreed to work together to use the Company’s proprietary drug discovery platform and library of chemical compounds to select targets for up to two additional collaboration programs. Pursuant to the terms of the Agreement, the Company and Roche have agreed to collaborate on the discovery, development and commercialization of up to five small molecule therapeutics targeting kinases believed to be important in cancer immunotherapy, as single products or possibly in combination with other therapeutics (the “Collaboration”). ![]() Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. On March 14, 2016, Blueprint Medicines Corporation (the “Company”) entered into a Collaboration and License Agreement (the “Agreement”) with F. Item 1.01 Entry into a Material Definitive Agreement. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |